A bipartisan senator introduced it Health Technology Investment Method (S. 1399) establishes Medicare reimbursement routes for FDA-cleared medical devices that utilize artificial intelligence and machine learning.
The bill, introduced by Martin Heinrich of Mike Rounds sD and Dn.M., seeks to amend the Social Security Act title XVIII to “ensure proper payments for certain algorithm-based healthcare services under the Medicare program.”
Through the bill, the Secretary of Health and Human Services will assign qualified algorithm-based devices to the outpatient payment classification (APC) of new technology, determined based on service manufacturers’ cost data.
Such data includes billing prices, subscription-based fees, overhead costs, clinical staff fees, and other costs associated with the provision of services.
The bill states that services must remain in the new technology APC for at least five years and cannot be removed until data is properly reassigned until it becomes available.
The Act also states that if approved, HHS Secretaries will coordinate the application process and the standards for new technology APCs to allow AI-enabled services at defined start, center and termination.
It is also necessary that the service “is provided, but is provided, or provided, as part of the underlying service, at the same time, or at the same time as other modalities or forms, and is provided, and is being provided, as well as those that require additional resources.”
Bigger trends
Another proposed law, HR238focusing on the use of AI in healthcare, was introduced in the U.S. House of Representatives earlier this year. AI and machine learning technologies will allow for prescribing drugs autonomously approved by the FDA.
The bill amends the Federal Food, Drugs and Cosmetics Act (FFDCA) to “ensure that artificial intelligence and machine learning technologies are eligible as practitioners and that drugs are prescribed if relevant for food and other purposes, if approved, approved or approved by a state approved or approved.”
If approved, section 503(b) of the FFDCA will be amended to recognize the AI ​​as “a legally licensed practitioner to administer such a drug.”
